

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on March 10, 2004

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Examining Group 1651

Patent Application

Docket No. USF-T173CXC1

Serial No. 09/914,508

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Vera Afremova  
Art Unit : 1651  
Applicants : Beerelli Seshi  
Serial No. : 09/914,508  
Filed : November 7, 2001  
Conf. No. : 8090  
For : Human Mesenchymal Progenitor Cell

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

Glenn P. Ladwig

Glenn P. Ladwig  
Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

GPL/mv

Attachments: Form PTO/SB/08 (5 pages); copies of references cited therein.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/914,508
				Filing Date	November 7, 2001
				First Named Inventor	Beerelli Seshi
				Art Unit	1651
				Examiner Name	Vera Afremova
Sheet	1	of	5	Attorney Docket Number	USF-T173CXC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-5,521,067	05-28-1996	Seshi	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			<b>Application Number</b>	09/914,508	
			<b>Filing Date</b>	November 7, 2001	
			<b>First Named Inventor</b>	Beerelli Seshi	
			<b>Group Art Unit</b>	1651	
			<b>Examiner Name</b>	Vera Afremova	
<b>Sheet</b>	2	<b>of</b>	5	<b>Attorney Docket Number</b>	USF-T173CXC1


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	CHAKRABARTI, O. and S. KRISHNA "Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression" <i>J. Biosci.</i> , 2003, 28(3):337-348.	
	R2	CHARBORD, P. <i>et al.</i> "Stromal cells from human long-term marrow cultures, but not cultured marrow fibroblasts, phagocytose horse serum constituents: studies with a monoclonal antibody that reacts with a species-specific epitope common to multiple horse serum proteins" <i>Exp. Hematol.</i> , 1987, 15:72-77.	
	R3	CONGET, P.A. and J.J. MINGUELL "Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells" <i>J. Cell. Physiol.</i> , October 1999, 181:67-73.	
	R4	DENNIS, J.E. <i>et al.</i> "A quadripotential mesenchymal progenitor cell isolated from the marrow of an adult mouse" <i>J. Bone and Mineral Res.</i> , 1999, 14(5):700-709.	
	R5	DEUNSING, S. and K. MUNGER "The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability" <i>Cancer Res.</i> , 2002, 62:7075-7082.	
	R6	DEUNSING, S. <i>et al.</i> "The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle" <i>PNAS</i> , 2000, 97(18):10002-10007.	
	R7	DORSHKIND, K. "Multilineage development from adult bone marrow cells" <i>Nature Immunology</i> , 2002, 3(4):311-313.	
	R8	DURST, M. <i>et al.</i> "Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV-positive human cell lines" <i>J. Virology</i> , 1991, 65(2):796-804.	
	R9	FRIEDENSTEIN, A.J. <i>et al.</i> "Fibroblast precursors in normal and irradiated mouse hematopoietic organs" <i>Exp. Hemat.</i> , 1976, 4:267-274.	
	R10	EAVES, A.C. and C.J. EAVES "Maintenance and proliferation control of primitive hemopoietic progenitors in long-term cultures of human marrow cells" <i>Blood Cells</i> , 1988, 14:355-368.	
	R11	GERSON, S.L. "Mesenchymal stem cells: No longer second class marrow citizens" <i>Nature Med.</i> , 1999, 5(3):262-264.	
	R12	GRAF, L. <i>et al.</i> "Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a" <i>Blood</i> , 2002, 100(4):1509-1511.	
	R13	GRAVITT, P. "HPV: The ultimate cancer initiator?" <i>HPV Today</i> , No. 3, September 2003, pp. 1-4.	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/914,508
Filing Date	November 7, 2001
First Named Inventor	Beerelli Seshi
Group Art Unit	1651
Examiner Name	Vera Afremova
Attorney Docket Number	USF-T173CXC1

Sheet 3 of 5

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R14	HAYNESWORTH, S.E. <i>et al.</i> "Characterization of cells with osteogenic potential from human marrow" <i>Bone</i> , 1992, 13:81-88.	
	R15	HAYNESWORTH, S.E. <i>et al.</i> "Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies" <i>Bone</i> , 1992, 13:69-80.	
	R16	HENDERSON, A.J. <i>et al.</i> "Functional characterization of two stromal cell lines that support B lymphopoiesis" <i>J. Immunology</i> , 1990, 145:423-428.	
	R17	HICOK, K.C. <i>et al.</i> "Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma" <i>J. Bone and Mineral Res.</i> , 1998, 13(2):205-217.	
	R18	HORWITZ, E.M. <i>et al.</i> "Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta" <i>Nature Med.</i> , 1999, 5(3):309-313.	
	R19	IWATA, M. <i>et al.</i> "Functional interleukin-7 receptors (IL7R) are expressed by marrow stromal cells: binding of IL-7 increases levels of IL-6 mRNA and secreted protein" August 2002 (epub date May 2002), 100:1318-1325.	
	R20	KEATING, A. <i>et al.</i> "Donor origin of the <i>in vitro</i> haematopoietic microenvironment after marrow transplantation in man" <i>Nature</i> , 1982, 298:280-283.	
	R21	KELLY, K.A. and J.M. GIMBLE "1,25-Dihydroxy vitamin D <sub>3</sub> inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures" <i>Endocrinology</i> , 1998, 139:2622-2628.	
	R22	KOÇ, O.N. <i>et al.</i> "Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases" <i>Exp. Hematology</i> , 1999, 27:1675-1681.	✓
	R23	KOPEN, G.C. <i>et al.</i> "Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains" <i>Proc. Natl. Acad. Sci. USA</i> , 1999, 96:10711-10716.	✓
	R24	LIESVELD, J.L. <i>et al.</i> "Characterization of human marrow stromal cells: Role in progenitor cell binding and granulopoiesis" <i>Blood</i> , 1989, 73(7):1794-1800.	
	R25	MOORE, M.A.S. <i>et al.</i> "Prolonged hematopoiesis in a primate bone marrow culture system: Characteristics of stem cell production and the hematopoietic microenvironment" <i>Blood</i> , 1979, 54(4):775-793.	
	R26	PARK, S.R. <i>et al.</i> "Interconversion potential of cloned human marrow adipocytes <i>in vitro</i> " <i>Bone</i> , 1999, 24(6):549-554.	


Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/914,508		
		Filing Date	November 7, 2001		
		First Named Inventor	Beerelli Seshi		
		Group Art Unit	1651		
		Examiner Name	Vera Afremova		
Sheet	4	of	5	Attorney Docket Number	USF-T173CXC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R27	PENN, P.E. <i>et al.</i> "Dissecting the hematopoietic microenvironment. IX. Further characterization of murine bone marrow stromal cells" <i>Blood</i> , 1993, 81(5):1205-1213.	
	R28	PESSINA, A. <i>et al.</i> "Expression of B cell markers on SR-4987 cells derived from murine bone marrow stroma" <i>Exp. Hematology</i> , 1997, 25:536-541.	
	R29	PROCKOP, D.J. "Marrow stromal cells as stem cells for nonhematopoietic tissues" <i>Science</i> , 1997, 276:71-74.	
	R30	ROECKLEIN, B.A. and B. TOROK-STORB "Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes" <i>Blood</i> , 1995, 85(4):997-1005.	
	R31	SESHI, B. <i>et al.</i> "Multilineage gene expression in human bone marrow stromal cells as evidenced by single-cell microarray analysis" <i>Blood Cells, Molecules, and Diseases</i> , 2003, 31:268-285.	
	R32	SILER, U. <i>et al.</i> "Laminin $\gamma$ 2 chain as a stromal cell marker of the human bone marrow microenvironment" <i>Brit. J. Haematology</i> , 2002, 119:212-220.	
	R33	SIMMONS, P.J. <i>et al.</i> "Host origin of marrow stromal cells following allogeneic bone marrow transplantation" <i>Nature</i> , 1987, 328:429-432.	
	R34	SINGER, J.W. <i>et al.</i> "Evidence for a stem cell common to hematopoiesis and its <i>in vitro</i> microenvironment: Studies of patients with clonal hematopoietic neoplasia" <i>Leukemia Res.</i> , 1985, 8(4):535-545.	
	R35	STEDMAN, T.L., Stedman's Medical Dictionary, 5 <sup>th</sup> Edition, 1984, pp. 931-932.	
	R36	STOPPLER, H. <i>et al.</i> "The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length" <i>J. Biol. Chem.</i> , 1997, 272(20):13332-13337.	
	R37	TAICHMAN, R.S. <i>et al.</i> "Human osteoblasts support human hematopoietic progenitor cells in <i>in vitro</i> bone marrow cultures" <i>Blood</i> , 1996, 87(2):518-524.	
	R38	TOROK-STORB, B., ATCC Catalog, ATCC Number CRL-2496.	
	R39	TOROK-STORB, B. <i>et al.</i> "Dissecting the marrow microenvironment" <i>Ann. NY Acad. Sci.</i> , 1999, 872:164-170.	


Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	09/914,508	
			Filing Date	November 7, 2001	
			First Named Inventor	Beerelli Seshi	
			Group Art Unit	1651	
			Examiner Name	Vera Afremova	
Sheet	5	of	5	Attorney Docket Number	USF-T173CXC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R40	TAICHMAN, R.S. and S.G. EMERSON "Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor" <i>J. Exp. Med.</i> , 1994, 179:1677-1682.	
	R41	TERADA, N. <i>et al.</i> "Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion" <i>Nature</i> , 2002, 416:542-545.	
	R42	THOMAS, T. <i>et al.</i> "Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes" <i>Endocrinology</i> , 1999, 140:1630-1638.	
	R43	TREMAIN, N. <i>et al.</i> "MicroSAGE analysis of 2,353 expressed genes in a single cell-derived colony of undifferentiated human mesenchymal stem cells reveals mRNAs of multiple cell lineages" <i>Stem Cells</i> , 2001, 19:408-418.	
	R44	WINEMAN, J. <i>et al.</i> "Functional heterogeneity of the hematopoietic microenvironment: Rare stromal elements maintain long-term repopulating stem cells" <i>Blood</i> , 1996, 87(10):4082-4090.	
	R45	WOODBURY, D. <i>et al.</i> "Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis" <i>J. Neuroscience Res.</i> , 2002, 96:908-917.	
	R46	YAMAZAKI, K. <i>et al.</i> "A comparative morphometric study on the ultrastructure of adherent cells in long-term bone marrow culture from normal and congenitally anemic mice" <i>Blood Cells</i> , 1989, 15:343-364.	
	R47		
	R48		
	R49		
	R50		
	R51		
	R52		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.